Palbociclib, ribociclib, and abemaciclib, three orally highly selective CDK4/6 inhibitors, were recently authorized by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to treat hormone receptor (HR)-positive advanced or metastatic BC [10]. The gene discussed is CDK4; the disease is breast cancer.